about
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes RegisterRange of Risk Factor Levels: Control, Mortality, and Cardiovascular Outcomes in Type 1 Diabetes Mellitus.Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study.Durability of oral hypoglycemic agents in drug naïve patients with type 2 diabetes: report from the Swedish National Diabetes Register (NDR).Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes RegisterBlood pressure and complications in individuals with type 2 diabetes and no previous cardiovascular disease: national population based cohort study.Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study.Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study.Ongoing treatment with renin-angiotensin-aldosterone-blocking agents does not predict normoalbuminuric renal impairment in a general type 2 diabetes population.Body mass index as a risk factor for coronary events and mortality in patients with type 1 diabetes.PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease.Association between refill adherence to lipid-lowering medications and the risk of cardiovascular disease and mortality in Swedish patients with type 2 diabetes mellitus: a nationwide cohort study.Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
P50
Q28477948-9B14377D-BF14-400F-9340-D1B8F3C5A2E6Q33590908-FEDEC1EC-3CD4-4396-BA6B-026B29FDC9E9Q33814995-E2161B7F-724C-4C7D-B43D-DF107F98588AQ35203980-E393635B-45D9-49EE-A0AB-13D60FF970EEQ36809851-59CA1DB6-696F-4388-88B4-842308C259D4Q37154677-7E8A59D2-FAEB-4B9A-892A-E9FAFC1D8D22Q38629283-12EC38B8-1722-438C-8E4B-9C31CCFF1C2BQ40246024-F72D0152-C98D-4FE8-818A-269C8182E26AQ40419062-D1902BFB-E23E-45D4-8972-21B95D6B7B80Q43918662-0F4B7754-E83F-4012-BCE4-826174CA17D8Q48129352-5761A55D-4D45-4127-B00A-B08BE03C139DQ48678750-CD36E569-B4F4-4AB3-AE84-206D8CB53254Q53833642-15B0DB1B-3575-4DCB-AE82-350A1A7730F3Q54383946-91307780-5BB7-4705-BE04-9A3E8AE02729Q59803697-58AB7B81-1E59-4193-9883-02FEE55CF16F
P50
description
researcher ORCID ID = 0000-0003-4028-8945
@en
wetenschapper
@nl
name
Mervete Miftaraj
@ast
Mervete Miftaraj
@en
Mervete Miftaraj
@es
Mervete Miftaraj
@nl
type
label
Mervete Miftaraj
@ast
Mervete Miftaraj
@en
Mervete Miftaraj
@es
Mervete Miftaraj
@nl
prefLabel
Mervete Miftaraj
@ast
Mervete Miftaraj
@en
Mervete Miftaraj
@es
Mervete Miftaraj
@nl
P31
P496
0000-0003-4028-8945